FS KKR Prices the Bad Quarter, Not the Backstop

Summary: FSK last traded at $10.72 in a live finance snapshot checked at May 14, 2026 16:49 Singapore time. That is only 2.6% below KKR Alternative Assets' live $11.00 tender price, but the real disagreement is larger than a tender spread. KKR's broader package includes $150 million of new preferred stock with an initial conversion price tied to $18.83 March 31 NAV, a $300 million follow-on common-stock repurchase authorization, and a four-quarter waiver on 50% of the subordinated income incentive fee. Put together, that is roughly $600 million of sponsor-linked support against a market capitalization of about $3.0 billion, yet the common still trades at only about 0.57x quarter-end NAV. FS KKR strategic value enhancement actions, May 11, 2026 KKR Alternative Assets Schedule TO, May 12, 2026

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Asymmetry	Main Reason to Reject
1	FS KKR prices the bad quarter, not the backstop	U.S. BDC / tender / sponsor support / buyback	`FSK` still trades at $10.72 even after KKR launched an $11.00 tender, agreed to buy $150 million of preferred stock at a conversion price tied to $18.83 NAV, authorized a $300 million buyback, and accepted a four-quarter fee waiver.	Official company and SEC documents dated May 11-12, 2026 and live price checked May 14, 2026 Singapore time.	Tender expires June 9, 2026 New York time, preferred closes after the tender, and the open-market buyback can start after expiration.	The sponsor complex is stepping in at a valuation well above the public quote while the stock still trades at only 0.57x NAV.	The quarter was genuinely bad, the tender is prorated if oversubscribed, and more credit marks could still hit book value.
2	RRHI prices the tender, not the dividend	Broader Asia / Philippines consumer / take-private / tender / dividend	`RRHI` was quoted at PHP47.75 on the latest official market page I could verify during this run, while the disclosed path is a PHP48.30 tender plus a separate PHP2.00 cash dividend.	Official April 2026 information statement, official April 29 dividend declaration, and official stock page checked May 14, 2026 Singapore time.	Tender expected to commence on or around May 25, 2026; dividend ex-date May 27; record date May 28.	The total cash path can reach PHP50.30 if the mechanics hold.	The offer still depends on regulatory clearance and a 95% ownership threshold, so the downside branch is too large for the headline spread.
3	VH Global still trades too wide to realization value	Europe / U.K. infrastructure fund / asset realization / B-share scheme	`ENRG` last traded at 74.79p while the company reported estimated NAV of 102.941p and now has an effective capital reduction to support B-share cash returns from asset sales.	Official factsheet and official capital-reduction notice through May 2026 plus latest quote checked during this run.	Asset sales, B-share distributions, and ongoing realization updates.	The discount to stated value is large.	The closing mechanism is slower and mark-to-model risk is higher than in FSK.
4	Aisin's capital return is real, but the tender sits below the tape	Japan large-cap auto supplier / tender offer / treasury-stock cancellation	Aisin's tender offer is set at JPY1,986, but the stock was trading around JPY2,310.5 when checked during this run.	Official April 28, 2026 tender notice and live quote page checked May 14, 2026.	Tender period already underway.	The buyback is real.	Public holders are being asked to anchor to a price below the live tape, so this is not a clean long.

Selected opportunity: FS KKR prices the bad quarter, not the backstop.

Why this one now: It is the best new idea on the board after the duplicate-title scan because the market is still fixated on a bad quarter even though the sponsor complex has already moved from rhetoric to actual capital.

What should surprise the reader: A sophisticated reader should pause at the same sponsor ecosystem being willing to buy common at $11.00, buy preferred with an initial conversion price of $18.83, waive fees for four quarters, and authorize another $300 million of common repurchases while the public stock still trades at $10.72.

Why This Is the Best Opportunity Right Now

FSK wins because the support is explicit, funded, and near-dated.

The quarter was ugly. March 31 NAV fell to $18.83 from $20.89 three months earlier. Total net realized and unrealized loss was $2.00 per share. Net debt to equity rose to 131%. Non-accruals rose to 4.2% of the portfolio at fair value from 3.4% at year-end. The market is not imagining the damage. FS KKR strategic value enhancement actions, May 11, 2026

But the response matters more than the fear headline. KKR Alternative Assets moved immediately with a $150 million tender at $11.00 per share. A KKR affiliate also agreed to buy $150 million of cumulative convertible perpetual preferred stock with an initial conversion price of $18.83, exactly equal to March 31 NAV. FSK's board then authorized a further $300 million stock repurchase program to start after the tender expires. The adviser also agreed to waive its share of half the subordinated income incentive fee for four consecutive quarters starting in Q2 2026. KKR Alternative Assets press release, May 11, 2026 FS KKR strategic value enhancement actions, May 11, 2026

RRHI is cleaner, but the upside is capped and the failure branch is real. VH Global is wider, but slower. Aisin has real capital return, but the tender price is already below the live tape. FSK is the only one where the sponsor is underwriting size at a much higher reference value while the public stock still trades as if the only fact that matters is the quarter-end markdown.

What Should Surprise the Reader

The surprise is not that FSK had a bad quarter.

The surprise is that after a bad quarter, the sponsor complex chose to do almost everything a skeptical shareholder would ask for at once: bid for common, inject fresh preferred capital, waive fees, and authorize a second repurchase program. Yet the common still trades at only about 57 cents on the dollar of quarter-end NAV.

That is not normal “management said the stock is cheap” language. It is capital committed on both the common and preferred sides of the stack.

The Setup

FSK is a large business development company. At March 31, 2026 it reported $12.269 billion of investments at fair value, with 63.7% invested in senior secured securities and a weighted average annual yield on accruing debt investments of 9.9%. This is not a tiny, illiquid wrapper. FS KKR strategic value enhancement actions, May 11, 2026

What changed is that the market lost patience with the credit marks. The company said the NAV decline was driven by problem investments that had already hurt prior quarters, new non-accrual assets, and spread widening in parts of the portfolio. That is why the support package exists. The sponsor is not buying a victory lap. It is buying into visible damage. FS KKR strategic value enhancement actions, May 11, 2026

The key question is whether the public quote has already discounted enough of that damage. At $10.72, the stock says yes. The sponsor package says maybe not.

The Market Price

Market Level	Current Reading	Source / Timestamp	Why It Matters
`FSK` live price	$10.72	OpenAI finance snapshot checked May 14, 2026 at 16:49 Singapore time	Current entry reference.
Tender price	$11.00	KKR Alternative Assets Schedule TO, May 12, 2026	Hard common-stock support price.
Gap to tender price	2.6%	Calculated from the two rows above	Shows why this is not just a wide arbitrage spread.
Tender size	$150 million	Schedule TO, May 12, 2026	Immediate sponsor bid for common stock.
Tender capacity	About 13.64 million shares	Calculated from $150 million / $11.00	Roughly 4.9% of shares outstanding.
Shares outstanding	280,066,433	Schedule TO, company data as of May 6, 2026	Needed to size the tender and market cap.
March 31 NAV per share	$18.83	Company Q1 results release, May 11, 2026	Anchor for valuation and preferred conversion.
Price / NAV	About 0.57x	Calculated from price and NAV	The market is still pricing a large impairment discount.
Preferred investment	$150 million	Company Q1 results release, May 11, 2026	Fresh sponsor capital going in above the common.
Initial preferred conversion price	$18.83	Company Q1 results release, May 11, 2026	Sponsor reference value is far above the tape.
Follow-on repurchase authorization	$300 million	Company Q1 results release, May 11, 2026	Additional common support after the tender.
Total sponsor-linked support package	About $600 million	Calculated from tender, preferred, and follow-on buyback	Roughly 20.0% of the current market cap.
Q2 distribution	$0.42 per share	Company Q1 results release, record June 17, 2026, pay July 2, 2026	Income holders still care about the dividend path.
Incentive fee waiver	50% of the subordinated income incentive fee for four quarters	Company Q1 results release, May 11, 2026	Supports near-term NII and the distribution.
Net debt to equity	131%	Company Q1 results release, May 11, 2026	This is why the market is skeptical.
Non-accruals at fair value	4.2%	Company Q1 results release, May 11, 2026	Credit pain is real, not imagined.

The Positioning

The positioning evidence here is corporate, not speculative.

I do not have a verified live read on short interest, stock borrow, or listed-options positioning during this run. This is not a squeeze thesis.

What I do have is more useful. The marginal buyer is no longer hypothetical. KKR Alternative Assets is bidding for common. A KKR affiliate is committing preferred capital with a conversion price at NAV. The adviser is giving up economics for four quarters. FSK's board is authorizing a second repurchase program. That is the positioning tension: wounded income holders are still staring at the quarter, while the sponsor complex is already acting like the discount is too wide. KKR Alternative Assets Schedule TO, May 12, 2026 FS KKR strategic value enhancement actions, May 11, 2026

The Catalyst

The catalyst ladder is visible.

The tender commenced on May 12, 2026 and expires at 11:59 p.m. New York City time on June 9, 2026, unless extended. If the offer is oversubscribed, acceptance is prorated, though the purchaser reserved the right to buy up to an additional 2% of FSK's outstanding shares without extending the offer. The preferred closing is expected on the eleventh business day after the tender expires, subject to conditions including HSR. The company also said the $300 million repurchase program will begin as soon as practicable after the tender expires. Tender summary advertisement, May 12, 2026 KKR Alternative Assets Schedule TO, May 12, 2026 FS KKR Capital 8-K, May 11, 2026

That sequence matters because it changes the question. Once the tender closes, the market no longer gets to talk about abstract support. It has to decide how much value to assign to a BDC that just received a visible sponsor backstop at a much higher reference price than the common quote.

The Gap

The market appears to be pricing FSK as if the quarter's markdown invalidates everything else.

That is too simple.

A sponsor can absolutely overpay, and preferred stock is not the same as common. But the gap is still striking. The public common trades at $10.72. The sponsor is willing to buy common at $11.00 now, preferred with an initial conversion price of $18.83 next, and then support another $300 million of buybacks after that. The same package also includes a fee waiver meant to support net investment income and the dividend. FS KKR strategic value enhancement actions, May 11, 2026

The market may still be right that book value needs to fall further. But if the quarter-end NAV is even roughly in the zone, the current common price is still treating the support package as mostly cosmetic.

The Payoff Map

One possible expression is long FSK common stock.

That is the cleanest expression because the thesis is not a pure tender spread. The tender is small relative to the share count and can be prorated. The better question is whether the stock should still trade at barely more than half of March 31 NAV after the sponsor complex has chosen to support both the common and preferred sides of the capital stack.

I did not use options as the lead structure. I did not safely verify a live options chain, current spreads, or executable premium levels during this run, and the thesis does not require forced convexity to work.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	25%	`FSK` $13.75	+28.3%	1 to 3 months	The tender closes cleanly, the preferred closes on schedule, the buyback begins, credit marks stabilize, and the market rerates the stock toward roughly 0.73x March 31 NAV.	Medium
Base Case	50%	`FSK` $12.40	+15.7%	1 to 3 months	The sponsor package removes the emergency-capital narrative, the tender and preferred both close, and the stock rerates only part of the way toward NAV, to roughly 0.66x March 31 NAV.	Medium / High
Bottom Case	25%	`FSK` $9.20	-14.2%	1 to 3 months	The quarter proves to be the start, not the end, of the markdown cycle, the support package is read as defensive rather than opportunistic, and BDC discounts stay wide or widen further.	Medium
Invalidation / Stop Condition	n/a	Sustained move below `FSK` $9.20 or new evidence that NAV erosion is outrunning the support package	n/a	n/a	The support package no longer offsets the fundamental deterioration.	Medium

Probability-weighted expected value: approximately +11.4%, using the scenario returns above.

Current market price / level: FSK $10.72.

Timestamp: checked May 14, 2026 at 16:49 Singapore time.

Primary instrument: FS KKR Capital common stock, FSK.

Alternative expressions considered: tendering common into the $11.00 offer, waiting until after June 9, or using listed options. Tendering only is too narrow because of proration and because accepted shares will not be around for the June 17 record date on the Q2 distribution. Waiting reduces event risk but gives up the rerating window if the market starts to respect the broader support package before the tender closes. Options were rejected as primary because live chain quality and spreads were not safely verified during this run.

Confidence: Medium.

What Could Go Wrong

The strongest counterargument is that the market is right and the sponsor is just paying to stop a spiral.

That argument has teeth. The quarter-end damage was real. Non-accruals rose. Leverage stayed high. The credit agreement had to be amended, including a lower shareholders' equity floor and a reduced total commitment size. Preferred stock also is not common stock. It sits senior to the common and carries a 5.00% cash dividend or 7.00% PIK if the company elects that route. A sponsor buying preferred at NAV does not prove the common deserves NAV. FS KKR strategic value enhancement actions, May 11, 2026

The tender itself is also easy to misunderstand. It is only $150 million and can be prorated. This is not a clean merger-arb exit. If too many holders tender, each one gets only part of the position accepted. That means the real thesis still lives in the residual stock. Letter of transmittal, May 12, 2026

What Would Prove This Wrong

This thesis fails if fresh evidence says the sponsor package is smaller than the credit hole.

It is wrong if one or more of the following happens:

the tender or preferred closing slips materially or breaks;
portfolio marks worsen enough that March 31 NAV is no longer a useful reference point;
the market keeps the stock below $9.20 even after the tender and follow-on buyback start;
or management disclosures show that supporting the buyback requires a deeper retrenchment in originations or balance-sheet flexibility than the market can tolerate.

That would mean the market is not ignoring the backstop. It is correctly deciding that the backstop is not big enough.

Bottom Line

FSK is not a pretty quarter recovery trade. It is a valuation disagreement with hard capital behind it. The market is staring at a real credit wobble. The sponsor complex is answering with an $11.00 common tender, $150 million of preferred priced off $18.83 NAV, a $300 million follow-on buyback, and a four-quarter fee waiver. At $10.72, the stock still prices only the damage.

Best trade strategy: Long FSK common stock. The thesis is about rerating after visible sponsor support, not about an options structure.